[{"id":"e1485158-d730-462d-be42-9cd0f137d814","acronym":"STRIvE-01","url":"https://clinicaltrials.gov/study/NCT03618381","created_at":"2021-01-18T17:46:54.866Z","updated_at":"2024-07-02T16:35:10.845Z","phase":"Phase 1","brief_title":"EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults","source_id_and_acronym":"NCT03618381 - STRIvE-01","lead_sponsor":"Seattle Children's Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR806-specific CAR T-cell therapy • SCRI-CARB7H3(s)x19 • SCRI-huCAR19v1"],"overall_status":"Recruiting","enrollment":" Enrollment 44","initiation":"Initiation: 06/18/2019","start_date":" 06/18/2019","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 06/01/2040","study_completion_date":" 06/01/2040","last_update_posted":"2024-04-09"},{"id":"9d7802e8-9cf0-441c-8363-c53cf3be3c5c","acronym":"","url":"https://clinicaltrials.gov/study/NCT03638167","created_at":"2021-01-18T17:51:52.507Z","updated_at":"2024-07-02T16:35:31.308Z","phase":"Phase 1","brief_title":"EGFR806-specific CAR T Cell Locoregional Immunotherapy for EGFR-positive Recurrent or Refractory Pediatric CNS Tumors","source_id_and_acronym":"NCT03638167","lead_sponsor":"Seattle Children's Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR expression • EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR806-specific CAR T-cell therapy"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 03/19/2019","start_date":" 03/19/2019","primary_txt":" Primary completion: 03/01/2025","primary_completion_date":" 03/01/2025","study_txt":" Completion: 03/01/2040","study_completion_date":" 03/01/2040","last_update_posted":"2023-10-27"},{"id":"2ac1606a-0606-46ec-aac6-2458374bdc46","acronym":"","url":"https://clinicaltrials.gov/study/NCT05341492","created_at":"2022-04-22T13:53:34.891Z","updated_at":"2024-07-02T16:35:54.546Z","phase":"Phase 1","brief_title":"EGFR/B7H3 CAR-T on Lung Cancer and Triple Negative Breast Cancer","source_id_and_acronym":"NCT05341492","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • CD276","pipe":" | ","alterations":" EGFR expression • CD276 expression","tags":["EGFR • CD276"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression • CD276 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Undisclosed EGFR/B7H3 CAR-T"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 05/01/2022","start_date":" 05/01/2022","primary_txt":" Primary completion: 05/01/2025","primary_completion_date":" 05/01/2025","study_txt":" Completion: 05/01/2025","study_completion_date":" 05/01/2025","last_update_posted":"2023-02-28"},{"id":"98f8a6d9-65fb-494a-8761-276771f22984","acronym":"","url":"https://clinicaltrials.gov/study/NCT05060796","created_at":"2021-09-29T11:53:48.510Z","updated_at":"2024-07-02T16:35:54.523Z","phase":"Phase 1","brief_title":"Study of CXCR5 Modified EGFR Targeted CAR-T Cells for Advanced NSCLC","source_id_and_acronym":"NCT05060796","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • CXCL13","pipe":" | ","alterations":" EGFR expression","tags":["EGFR • CXCL13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"],"overall_status":"Recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 09/01/2019","start_date":" 09/01/2019","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2034","study_completion_date":" 11/01/2034","last_update_posted":"2023-02-28"},{"id":"0e2c53e2-5daa-4613-9cf4-4a3a1038b338","acronym":"","url":"https://clinicaltrials.gov/study/NCT03198052","created_at":"2021-01-18T15:46:10.109Z","updated_at":"2024-07-02T16:35:55.664Z","phase":"Phase 1","brief_title":"GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T Cells Against Cancers","source_id_and_acronym":"NCT03198052","lead_sponsor":"Second Affiliated Hospital of Guangzhou Medical University","biomarkers":" EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA","pipe":" | ","alterations":" MSLN expression • EGFR positive • GPC3 expression","tags":["EGFR • HER-2 • CLDN18 • AXL • MSLN • MUC1 • CD276 • GPC3 • GUCY2C • PSCA"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MSLN expression • EGFR positive • GPC3 expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e GPC3/Mesothelin/Claudin18.2/GUCY2C/B7-H3/PSCA/PSMA/MUC1/TGFβ/HER2/Lewis-Y/AXL/EGFR-CAR-T cells"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 07/01/2017","start_date":" 07/01/2017","primary_txt":" Primary completion: 08/01/2024","primary_completion_date":" 08/01/2024","study_txt":" Completion: 08/01/2026","study_completion_date":" 08/01/2026","last_update_posted":"2023-02-14"},{"id":"8de501de-dc24-4c4c-b0d5-267b52f9ac57","acronym":"","url":"https://clinicaltrials.gov/study/NCT04153799","created_at":"2021-01-18T20:16:16.281Z","updated_at":"2024-07-02T16:36:45.084Z","phase":"Phase 1","brief_title":"Study of CXCR5 Modified EGFE Chimeric Antigen Receptor Autologous T Cells in EGFR- Positive Patients With Advanced Non-small Cell Lung Cancer","source_id_and_acronym":"NCT04153799","lead_sponsor":"Sun Yat-sen University","biomarkers":" EGFR • CXCL13","pipe":" | ","alterations":" EGFR expression","tags":["EGFR • CXCL13"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR expression"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e CXCR5 Modified EGFR Targeted CAR-T Cells"],"overall_status":"Recruiting","enrollment":" Enrollment 11","initiation":"Initiation: 11/01/2019","start_date":" 11/01/2019","primary_txt":" Primary completion: 12/01/2021","primary_completion_date":" 12/01/2021","study_txt":" Completion: 12/01/2022","study_completion_date":" 12/01/2022","last_update_posted":"2020-05-12"},{"id":"b286a9fa-fb70-47be-8eeb-79a805f622b6","acronym":"EGFRCART","url":"https://clinicaltrials.gov/study/NCT03542799","created_at":"2021-01-18T17:25:54.780Z","updated_at":"2024-07-02T16:37:10.392Z","phase":"Phase 1/2","brief_title":"EGFR-IL12-CART Cells for Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03542799 - EGFRCART","lead_sponsor":"Shenzhen Second People's Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR IL12 CART cells"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 05/22/2018","start_date":" 05/22/2018","primary_txt":" Primary completion: 05/23/2020","primary_completion_date":" 05/23/2020","study_txt":" Completion: 05/23/2021","study_completion_date":" 05/23/2021","last_update_posted":"2018-05-31"},{"id":"0aba850a-0541-42fe-8745-0f11e72ba677","acronym":"","url":"https://clinicaltrials.gov/study/NCT03152435","created_at":"2021-01-18T15:32:13.029Z","updated_at":"2024-07-02T16:37:18.811Z","phase":"Phase 1/2","brief_title":"EGFR CART Cells for Patients With Metastatic Colorectal Cancer","source_id_and_acronym":"NCT03152435","lead_sponsor":"Shenzhen Second People's Hospital","biomarkers":" EGFR","pipe":" | ","alterations":" EGFR positive","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR positive"],"overall_status":"Unknown status","enrollment":" Enrollment 20","initiation":"Initiation: 06/15/2017","start_date":" 06/15/2017","primary_txt":" Primary completion: 09/01/2019","primary_completion_date":" 09/01/2019","study_txt":" Completion: 12/01/2019","study_completion_date":" 12/01/2019","last_update_posted":"2017-08-16"},{"id":"7ed78b3f-22b6-4c6c-8145-bdab00f975a2","acronym":"","url":"https://clinicaltrials.gov/study/NCT03182816","created_at":"2021-01-18T15:41:44.148Z","updated_at":"2024-07-02T16:37:21.236Z","phase":"Phase 1/2","brief_title":"CTLA-4 and PD-1 Antibodies Expressing EGFR-CAR-T Cells for EGFR Positive Advanced Solid Tumor","source_id_and_acronym":"NCT03182816","lead_sponsor":"Shanghai Cell Therapy Research Institute","biomarkers":" EGFR","pipe":"","alterations":" ","tags":["EGFR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cyclophosphamide"],"overall_status":"Unknown status","enrollment":" Enrollment 40","initiation":"Initiation: 06/07/2017","start_date":" 06/07/2017","primary_txt":" Primary completion: 01/20/2019","primary_completion_date":" 01/20/2019","study_txt":" Completion: 04/20/2019","study_completion_date":" 04/20/2019","last_update_posted":"2017-06-09"}]